Topographical distribution of neurochemical changes in Alzheimer's disease
References (53)
- et al.
Somatostatin and vasoactive intestinal polypeptide in post-mortem brains from patients with Alzheimer-type dementia
Neurosci. Lett.
(1984) - et al.
Ratio of pyramidal cell versus nonpyramidal cells in the human frontal cortex and changes in ratio with ageing and Alzheimer's disease
- et al.
Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type
J. Neurol. Sci.
(1984) - et al.
Somatostatin content and release measured in cerebral biopsies from demented patients
J. Neurol. Sci.
(1987) - et al.
Substrate mediated regulation of phosphate-activated glutaminase in nervous tissue
Brain Res.
(1980) - et al.
Loss of hippocampal [3H]TCP binding in Alzheimer's disease
Neurosci. Lett.
(1987) - et al.
Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease
Neurosci. Lett.
(1986) - et al.
Catecholaminergic neurones assessed antemortem in Alzheimer's disease
Brain Res.
(1987) - et al.
Cortical serotonin S2 receptor binding abnormalities in patients with Alzheimer's disease
Neurosci. Lett.
(1984) - et al.
Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type
Neurosci. Lett.
(1984)
Characterisation and regional distribution of serotonin S2 receptors in human brain
Brain Res.
The evoked release of endogenous amino acids from tissue prisms of human neocortex
Brain Res.
Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease
Brain Res.
A comparison of sodium-dependent glutamate binding with high-affinity glutamate uptake in rat striatum
Brain Res.
[3H]ketanserin binding increases in monkey cortex following basal forebrain lesions with lbotenic acid
Neurochem. Int.
Immunocytochemical localization of aspartate aminotransferase and glutaminase immunoreactivites in the cerebellum
Brain Res.
Plaques, tangles and dementia
A quantitative study
J. Neurol. Sci.
Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease
Ann. Neurol.
Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease
Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease
J. Neurochem.
Neurotransmitter and metabolic dysfunction in Alzheimer's dementia: Relationship to histopathological features
(-)-Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor
Nature
An overview of light and electron microscopic changes
Positron emission tomography in aging and dementia: effect of cerebral atrophy
J. Nucl. Med.
Serotonin receptor changes in dementia of the Alzheimer's type
J. Neurochem.
The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia
Neurobiol. Aging
Cited by (128)
Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice
2013, Brain ResearchCitation Excerpt :Particularly the cholinergic basal nucleus of Meynert and septal nuclei with projections to almost all cortical areas, the hippocampus and the thalamus are severely impaired in a subset of AD brains (Herholz, 2008; McGeer et al., 1984). The loss and functional disturbance of cholinergic forebrain neurons is associated with a reduction of cholinergic neurotransmission, choline acetyltransferase and acetylcholinesterase enzyme activity (Francis et al., 1999; Herholz, 2008; Procter et al., 1988). Likewise, the content of the catecholamine noradrenaline is reduced in AD temporal and frontal cortices (Palmer and DeKosky, 1993).
The serotonergic system in ageing and Alzheimer's disease
2012, Progress in NeurobiologyCitation Excerpt :The use of 5-HT1A receptor antagonists has given promising results in preclinical studies in rodents and non-human primates, as well as in the clinical trials of AD patients (Hirst et al., 2008; Luttgen et al., 2005a; Madjid et al., 2006; Millan et al., 2004; Misane and Ogren, 2003). Autoradiographic binding studies using 5-HT2A receptor antagonist [3H]-ketanserin have consistently demonstrated reductions in 5-HT2A receptor density in the temporal, frontal and parietal cortex as well as amygdala, entorhinal cortex and in the hippocampus of post-mortem AD brains (Table 7) (Cheng et al., 1991; Cross et al., 1986; Crow et al., 1984; Dewar et al., 1990; Procter et al., 1988). Reduced 5-HT2A receptor density has been further confirmed by PET (Blin et al., 1993; Marner et al., 2010a; Meltzer et al., 1999; Santhosh et al., 2009), SPECT (Versijpt et al., 2003) and magnetic resonance imaging (MRI) (Hasselbalch et al., 2008).
Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type
2011, Ageing Research ReviewsCitation Excerpt :Psychosis frequently occurs subsequent to the onset of dementia. Published prevalence estimates of psychosis in patients with AD range from 10% to 73% with an overall median of 34% within clinic populations, and from 7% to 20% in community and clinical trials populations depending on definitions used (Procter et al., 1988). Neuroimaging, pharmacological and biochemical observations imply that cholinergic deficiency has a role in the development of psychosis.
Krill phosphatidylserine improves learning and memory in Morris water maze in aged rats
2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry